STIM
INSIDER BUYNeuronetics, Inc.
Research: Finviz ↗·Perplexity ↗
No convergence signal this quarter — shown because tracked funds have filed 13D/G on this stock.
News Summary
PositiveNeuronetics achieved its first positive adjusted EBITDA ($0.3M) in Q2 2026 with revenue beating consensus ($41.6M vs. $40.2M est.) and gross margins improving to 51.1%, supported by a leadership overhaul (new CFO from Axogen with strong M&A track record) and tightened full-year guidance emphasizing profitability. However, the company remains unprofitable on a GAAP basis, NeuroStar revenue declined 2.7% YoY, cash balances fell sharply to $25M, and one sell rating persists among five analyst covers despite modest price-target increases.
Red flags
- •Cash balance declined ~27% sequentially from $34.1M (end-2025) to $25M (Q2 2026), signaling funding constraints despite positive adjusted EBITDA
- •NeuroStar core product revenue declined 2.7% YoY, indicating mature/declining segment offset only by Greenbrook clinic growth
- •Full-year cash flow guidance remains negative ($10.5M–$14.5M), implying the company is not yet self-sustaining
- •One sell rating among five analysts as of October 2026, despite recent upgrades
Insider Activity
Fund 13D/13G Filings (1)
Tracked funds' beneficial-ownership filings on this stock — disclosed within days of a position change, fresher than the quarterly 13F. Since Filing compares the stock to SPY from the filing date (shown for filings within the last 90 days).